Date: 2015-11-05
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: ABT-555
Action
mechanism: monoclonal antibody. ABT-555 is a monoclonal antibody directed againt RGMa. This protein is a member of the repulsive guidance molecule family. RGMa is a glycosylphosphatidylinositol-anchored glycoprotein that functions as an axon guidance protein in the developing and adult central nervous system. This protein may also function as a tumor suppressor in some cancers. Abbvie is investigating ABT-555 to treat spinal cord injuries and multiple sclerosis.
Disease: relapsing forms of multiple sclerosis (RFMS)
Therapeutic area: Neurodegenerative diseases
Country: USA
Trial
details: This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS) receiving maintenance glatiramer acetate (Copaxone®).(NCT02601885)
Latest
news: * On November 5, 2015, a Phase I trial sponsored by Abbvie has been published on the NIH website ClinicalTrials.gov for ABT-555 and is currently recruiting.
